Navigation Links
Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Date:12/8/2008

SAN DIEGO, Dec. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that Roche has dosed the first patient in a Phase 1 pharmacokinetic clinical trial with a subcutaneous formulation using Enhanze Technology of a biologic directed to a Roche exclusive target. This has triggered a milestone payment under the agreement.

Roche has also selected an additional exclusive target under the existing license and collaboration agreement. Under the terms of the agreement, Roche will pay Halozyme for exclusive, global rights for the application of its hyaluronidase enzyme, rHuPH20, to a fourth biologic target selected by Roche.

"Roche and Halozyme have successfully completed the necessary drug product formulation and preclinical studies required to initiate a clinical trial. Entering the clinic is a significant achievement and demonstrates Roche's strong commitment to a successful partnership," said Jonathan Lim, M.D., Halozyme's President and CEO. "We are very pleased with the progress that is being made through our collaboration. Roche is a global leader in the development of biologics and we are excited that they have selected a fourth exclusive target, in addition to the three already under development, further validating Halozyme's core technology."

Roche has also maintained its rights to other targets covered in the license and collaboration agreement. An aggregate payment of $10.25 million will be made to Halozyme for commencing a Phase 1 clinical trial, exercising exclusive global rights to a fourth biologic target and for annual maintenance fees.

Halozyme also announced that it has entered into a supply agreement with Roche to provide rHuPH20 for use in formu
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
2. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
3. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
7. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
8. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
9. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
10. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
11. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if he wants ... engaged, he should address any hearing loss he may be ... Hearing Institute (BHI) is delivering to men around the ... which leads up to and includes Father,s Day. This year, ... 16. To help men address their hearing ...
(Date:5/23/2013)... recently published clinical study conducted at TOPS Comprehensive Breast ... that 3D mammography (breast tomosynthesis) significantly reduces unnecessary recalls ... study, "Implementation of Breast Tomosynthesis in a Routine Screening ... Stephen L. Rose , MD, and published in ... Roentgenology (AJR). The AJR is the scientific journal ...
(Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... Findings Published in June Issue of Circulation , ... United Therapeutics Corporation (Nasdaq: UTHR ) and ... today announced the results of a pivotal 16-week study ... well tolerated, improved exercise capacity and improved time to ...
... Trust for America,s Health (TFAH) and the Robert Wood ... today which finds that Americans rank prevention as the ... increasing funding for prevention programs to reduce disease and ... poll, conducted by Greenberg Quinlan Rosner Research and Public ...
Cached Medicine Technology:Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 2Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 3Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 4Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 5Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 6New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 2New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 3New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 4New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 5
(Date:5/24/2013)... (PRWEB) May 24, 2013 Today marks ... all-new online Itinerary Builder. , The redesigned and ... create unique vacation itineraries on their computer or mobile ... , The interactive tool allows users to fill in ... browse through and select their choice of vacation packages, ...
(Date:5/24/2013)... American Fork, Utah (PRWEB) May 24, 2013 ... several years now and is excited to announce it’s new weight ... our product that we are offering our customers their money back ... says Dave Sherwin, CEO of HCG EZ Drops. “The HCG ... caloric intake; hence the 21 pounds in 21 days.” , The ...
(Date:5/23/2013)... Magnatag’s new magnetic 365-Day attendance and vacation monitor ... A Manufacturing Manager from Augusta GA told us, “We ... managers can check the board for themselves and we ... us and the board makes the record public so ... it has made a difference.” , “Our customers ...
(Date:5/23/2013)... FL (PRWEB) May 24, 2013 Internationally ... coaching educators in tennis for over 29 years, ... than 50 ATP & WTA players, Grand Slam winners, ... Italian Open Champions, 25 USTA National Junior Champions, 8 ... Junior Champions, including Sunshine Cup, Orange Bowl and Eddie ...
(Date:5/23/2013)... Orange County film studio and visual effects ... light leaks for Apple's Final Cut Pro X today. ... no longer have to worry about matching up the movement ... Said Christina Austin, CEO of Pixel Film Studios, "You have ... look." , ProLeak from Pixel Film Studios allows users to ...
Breaking Medicine News(10 mins):Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance 2Health News:Internationally Respected Tennis Coach, Nick Saviano Opens Summer Training Registration 2Health News:Pixel Film Studios Releases ProLeak Light Leaks for Final Cut Pro X Today 2
... CLARA, Calif., FURSTENFELDBRUCK, Germany and YOKOHAMA CITY,Japan, ... real-time,compression technology company, Schleifring und Apparatebau GmbH, ... medical and defense markets,and Tokyo Electron Device ... boards, today announced an agreement for the ...
... the May/June issue of Health Affairs reports on the ... what one might expect from chronic disease management programs ... news for state Medicaid leaders struggling to meet the ... that some disease management efforts, even among relatively low-risk ...
... ... Quality Act (CEQA)., LOS ANGELES, May 12 ... planned expansion of its,Holy Cross Medical Center even as Superior Court ... was significantly flawed.,The groundbreaking ceremony held today appears to be an ...
... Denmark, May 12, Warner Chilcott and LEO ... and Drug Administration (FDA) has approved the,New ... 0.005% and,betamethasone dipropionate 0.064%) Topical Suspension. LEO ... the FDA in July 2007. Taclonex Scalp(R) ...
... Board:,NTRZ), a world leader in stabilized rice bran (SRB), ... first quarter ended,March 31, 2008. Consolidated net revenues rose ... compared to consolidated net revenues of $2.0,million for the ... due to a $860,000 increase in sales of products ...
... Baptist Health South,Florida Inc., a health care system ... $7,775,000 to settle claims that it violated the,False Claims ... by paying,excessive compensation to an oncology group that was ... the Department of Justice,announced today. The payments were made ...
Cached Medicine News:Health News:Samplify Systems Announces Availability of Compression for Computed Tomography; Integrated Slip-Ring Solution to be Jointly Developed with Schleifring und Apparatebau and Tokyo Electron Device Ltd. 2Health News:Samplify Systems Announces Availability of Compression for Computed Tomography; Integrated Slip-Ring Solution to be Jointly Developed with Schleifring und Apparatebau and Tokyo Electron Device Ltd. 3Health News:Samplify Systems Announces Availability of Compression for Computed Tomography; Integrated Slip-Ring Solution to be Jointly Developed with Schleifring und Apparatebau and Tokyo Electron Device Ltd. 4Health News:Chronic disease management: Does it improve health and save money? 2Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 2Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 3Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 4Health News:NutraCea Announces First Quarter 2008 Financial Results 2Health News:NutraCea Announces First Quarter 2008 Financial Results 3Health News:NutraCea Announces First Quarter 2008 Financial Results 4Health News:NutraCea Announces First Quarter 2008 Financial Results 5Health News:NutraCea Announces First Quarter 2008 Financial Results 6Health News:Florida Hospital Group Pays U.S. $7,775,000 to Settle False Claims Act Allegations 2
... Triad Skull Clamp, compatible with the full ... of clamping force on all three skull ... the possibility of adjusting the force on ... be increased or decreased by adjusting the ...
A fully automated, benchtop instrument designed for high-volume urine testing, using Siemens' proven technology in dry-pad urine chemistry analysis....
... PocketChem UA is the first ... take up valuable lab bench space. ... the variability in results between operators ... on every run, corrects for ambient ...
... sensor catheters incorporate a lumen ... wire, or high-speed injection/guide wire. ... injection has two laterally opposed ... open-end pigtail extension for use ...
Medicine Products: